Health care giant Johnson & Johnson (NYSE: JNJ – $140.06) said they have agreed to acquire Ci:z Holdings Co., Ltd., a Japanese company focused on the marketing, development and distribution of a broad range of dermocosmetic, cosmetic and skin care products. The all-cash offer to buy all the outstanding shares of the company not already held by Johnson & Johnson for about $2.05 billion. The acquisition will include the Company’s range of brands comprising Dr.Ci:Labo, Labo Labo and Genomer line of skin care products. The Company’s skin care portfolio is expected to strengthen Johnson & Johnson’s market presence in Japan with key customers, and more broadly bolster its offering in science-based, efficacious dermocosmetic brands.
Conservative income-minded investors may want to take a look at JNJ. The equity offers a 2.6% yield and above-average total return prospects through 2021-2023. On a risk-adjusted basis, this high-quality stock is even more attractive.